Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP306382.RADRK4yqsLXfb7aqL5OcdxPvbQN9ryVNJY0QqOaEnbb8c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP306382.RADRK4yqsLXfb7aqL5OcdxPvbQN9ryVNJY0QqOaEnbb8c130_assertion type Assertion NP306382.RADRK4yqsLXfb7aqL5OcdxPvbQN9ryVNJY0QqOaEnbb8c130_head.
- NP306382.RADRK4yqsLXfb7aqL5OcdxPvbQN9ryVNJY0QqOaEnbb8c130_assertion description "[Including this patient, we administered 150 mg erlotinib daily to nine NSCLC patients with CNS metastases and measured the plasma and CSF concentrations just before administration on day 8.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP306382.RADRK4yqsLXfb7aqL5OcdxPvbQN9ryVNJY0QqOaEnbb8c130_provenance.
- NP306382.RADRK4yqsLXfb7aqL5OcdxPvbQN9ryVNJY0QqOaEnbb8c130_assertion evidence source_evidence_literature NP306382.RADRK4yqsLXfb7aqL5OcdxPvbQN9ryVNJY0QqOaEnbb8c130_provenance.
- NP306382.RADRK4yqsLXfb7aqL5OcdxPvbQN9ryVNJY0QqOaEnbb8c130_assertion SIO_000772 21681573 NP306382.RADRK4yqsLXfb7aqL5OcdxPvbQN9ryVNJY0QqOaEnbb8c130_provenance.
- NP306382.RADRK4yqsLXfb7aqL5OcdxPvbQN9ryVNJY0QqOaEnbb8c130_assertion wasDerivedFrom befree-20140225 NP306382.RADRK4yqsLXfb7aqL5OcdxPvbQN9ryVNJY0QqOaEnbb8c130_provenance.
- NP306382.RADRK4yqsLXfb7aqL5OcdxPvbQN9ryVNJY0QqOaEnbb8c130_assertion wasGeneratedBy ECO_0000203 NP306382.RADRK4yqsLXfb7aqL5OcdxPvbQN9ryVNJY0QqOaEnbb8c130_provenance.